The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer

Abstract Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non‐small‐cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD‐1) and its ligand (PD‐L1), have remarkable antitumor efficacy and have...

Full description

Bibliographic Details
Main Authors: Fajiu Li, Ying Chen, Juanjuan Wu, Chenghong Li, Shi Chen, Ziyang Zhu, Wei Qin, Min Liu, Bingzhu Hu, Shuang Liu, Wenzhao Zhong
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Chronic Diseases and Translational Medicine
Subjects:
immune checkpoint inhibitors
neoadjuvant treatment
non‐small‐cell lung cancer
Online Access:https://doi.org/10.1002/cdt3.19

Internet

https://doi.org/10.1002/cdt3.19

Similar Items